69
14. Grasso M. Bladder cancer: a major public health issue. Eur Urol. 2008; Suppl
7: 510-5.
15. Grignon DJ, Sakr W, Toth M, Ravery V, Angulo J, Shamsa F, et al. High levels
of tissue inhibitor of metalloproteinase-2 (timp-2) expression are associated
with poor outcome in invasive bladder cancer. Cancer Res. 1996; 56: 1654-9.
16. Hara I, Miyake H, Hara S, Arakawa S, Kamidono S. Significance of matrix
metalloproteinases and tissue inhibitors of metalloproteinase expression in the
recurrence of superficial transitional cell carcinoma of the bladder. J Urol.
2001; 165: 1769-72.
17. Jemal A, Siegel R, Ward E, Yongping H, Xu J, Thun MJ. Cancer statistics,
2009. CA Cancer J Clin. 2009; 59: 225-49.
18. Jucá M, Nunes BLBBP, Menezes HL de, Gomes EGA, Matos D.
Metaloproteinases 1 e 7 e câncer colorretal. Rev Bras Coloproct. 2008; 28:
353-62.
19. Kader AK, Shao L, Dinney CP, Schabath MB, Wang Y, Liu J, et al. Matrix
metalloproteinase polymorphisms and bladder cancer risk. Cancer Res. 2006;
66: 11644-8.
20. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer – seminar. Lancet.
2009; 374: 239-49.
21. Kanayama H, Yokota K, Kurokawa Y, Murakami Y, Nishitani M, Kagawa S.
Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of
metalloproteinase-2 expression in bladder cancer. Cancer. 1998; 82: 1359-66.
22. Kawamura K, Kamiya N, Suyama T, Shimbo M, Oosumi N, Suzuki H, et al. In
situ gelatinolytic activity correlates with tumor progression and prognosis in
patients with bladder cancer. J Urol. 2004;172:1480-4.
23. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder
cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005; 66
Suppl 1: 4-34.
24. Liu B. Commentary on metalloproteinaes and bladder carcinoma. J Urol. 1998;
160: 1219.
25. Lyman GH, Kuderer NM, Freedland SJ. Does treatment intensity matter in
superficial bladder cancer? Consensus, clinical practice, and confounding
[editorial]. J Natl Cancer Inst. 2009; 101: 543-5.
26. Lynch CF, Davila JA, Platz CE. Cancer of the urinary bladder. In: Ries LAG,
Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J (editors). SEER Survival
Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001,
Patient and Tumor Characteristics. National Cancer Institute, SEER Program,
NIH Pub. No. 07-6215, Bethesda, MD. 2007. Disponível em: